Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chimerigen
CD278 [ICOS] (human):Fc (human) (rec.) (non-lytic)
Product Details | |
---|---|
Synonyms | ICOS; Inducible T Cell Costimulator; CRP1; CD28-related Protein-1; AILIM |
Product Type | Protein |
Properties | |
Source/Host | CHO cells |
Sequence |
The extracellular domain of human CD278 [ICOS] (aa 21-139) is fused to the N-terminus of the Fc region of a mutant human IgG1. |
Crossreactivity | Human |
Biological Activity |
Shows the biological function of the CD278 moiety and exerts a prolonged circulating half-life caused by the modified Fc domain. |
Purity | ≥98% (SDS-PAGE) |
Endotoxin Content | <0.06EU/μg protein (LAL test; Lonza). |
Reconstitution | Reconstitute at 100μg/ml in sterile PBS. |
Formulation | Lyophilized from 0.2μm-filtered solution in PBS. |
Protein Negative Control | |
Other Product Data |
Non-lytic: Acts as a long lasting fusion protein which only binds to the receptor. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC). |
Declaration | Manufactured by Chimerigen. |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. |
Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
CD278, also called inducible costimulator (ICOS) or CRP1 (CD28-related protein-1), is a member of the growing CD28 family of immune costimulatory receptors. Other family members are CD28, CTLA-4 and PD-1. ICOS is expressed on most CD45RO+ cells. ICOS expression is upregulated within approximately 24-48 hours of activation on Th primed cells. B7-H2, a member of the B7 family of costimulatory ligands, has been identified as the ICOS ligand. The B7-H2/ICOS interaction appears to play roles in T cell dependent B cell activation and Th differentiation.